| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML
|
Zhang, Zhibo
|
|
|
8 |
4 |
p. 889-894
|
artikel
|
| 2 |
Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266-6274.
|
|
|
|
8 |
4 |
p. 829-831
|
artikel
|
| 3 |
Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
|
Banerjee, Rahul
|
|
|
8 |
4 |
p. 895-898
|
artikel
|
| 4 |
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
|
Short, Nicholas J.
|
|
|
8 |
4 |
p. 909-915
|
artikel
|
| 5 |
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
|
Phillips, Tycel J.
|
|
|
8 |
4 |
p. 867-877
|
artikel
|
| 6 |
A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help
|
Curran, Kevin J.
|
|
|
8 |
4 |
p. 1053-1061
|
artikel
|
| 7 |
A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation
|
de Laat-Kremers, Romy M. W.
|
|
|
8 |
4 |
p. 936-946
|
artikel
|
| 8 |
Bridging therapy before axi-cel for lymphoma
|
Belbachir, Safia
|
|
|
8 |
4 |
p. 1051-1052
|
artikel
|
| 9 |
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
|
Jain, Michael D.
|
|
|
8 |
4 |
p. 1042-1050
|
artikel
|
| 10 |
Choosing the right mouse model: comparison of humanized NSG and NBSGW mice for in vivo HSC gene therapy
|
Choo, Seunga
|
|
|
8 |
4 |
p. 916-926
|
artikel
|
| 11 |
CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model
|
Neidemire-Colley, Lotus
|
|
|
8 |
4 |
p. 947-958
|
artikel
|
| 12 |
Estimation of eligibility for and response to CAR-T therapy in the United States
|
Haslam, Alyson
|
|
|
8 |
4 |
p. 1032-1036
|
artikel
|
| 13 |
FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia
|
Ramanagoudr-Bhojappa, Ramanagouda
|
|
|
8 |
4 |
p. 899-908
|
artikel
|
| 14 |
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
|
Ahn, Inhye E.
|
|
|
8 |
4 |
p. 832-841
|
artikel
|
| 15 |
High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer
|
Stonestrom, Aaron J.
|
|
|
8 |
4 |
p. 846-856
|
artikel
|
| 16 |
Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients
|
Zinter, Matt S.
|
|
|
8 |
4 |
p. 1002-1017
|
artikel
|
| 17 |
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
|
Herling, Marco
|
|
|
8 |
4 |
p. 842-845
|
artikel
|
| 18 |
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel
|
Sharma, Deva
|
|
|
8 |
4 |
p. 1018-1029
|
artikel
|
| 19 |
Maybe you can’t drive this CAR?
|
Derman, Benjamin A.
|
|
|
8 |
4 |
p. 1030-1031
|
artikel
|
| 20 |
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study
|
Pagani, Chiara
|
|
|
8 |
4 |
p. 968-977
|
artikel
|
| 21 |
Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice
|
Huang, Lulu
|
|
|
8 |
4 |
p. 991-1001
|
artikel
|
| 22 |
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
|
Bataller, Alex
|
|
|
8 |
4 |
p. 927-935
|
artikel
|
| 23 |
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
|
Garcia, Jacqueline S.
|
|
|
8 |
4 |
p. 978-990
|
artikel
|
| 24 |
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
|
Bhattacharya, Romit
|
|
|
8 |
4 |
p. 959-967
|
artikel
|
| 25 |
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs
|
Prosty, Connor
|
|
|
8 |
4 |
p. 857-866
|
artikel
|
| 26 |
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
|
Shotton, Rohan
|
|
|
8 |
4 |
p. 878-888
|
artikel
|
| 27 |
Survival in Agent Orange exposed and unexposed Vietnam-era veterans who were diagnosed with lymphoid malignancies
|
Ma, Helen
|
|
|
8 |
4 |
p. 1037-1041
|
artikel
|
Tijdschrift beschrijving